It uses real human skin and immune cells to show any reaction such as a rash or blistering indicating a wider immune response within the body.
The development is timely as it offers a reliable alternative for the cosmetic industry as a ban on the sale of any cosmetic product tested on animals came into effect across Europe in March.
Professor Anne Dickinson from the Institute of Cellular Medicine recently presented the technology at the In-Vitro Testing Industrial Platform (IVTIP) conference in Brussels. She said: "This skin assay offers an accurate and rapid alternative to animal testing and provides the bridge between the laboratory tests for novel drugs and the first stage of clinical trials in humans.
"It is accurate and faster than anything currently around and can save companies time and resources. The test identifies drugs or products which are likely to cause a reaction or just not work effectively in humans."
The test called Skimune™, which is trademarked and has a patent pending, has been successfully tested by a number of large pharmaceutical companies on drugs in development and provides a reliable result within two weeks.
By revealing skin sensitisation or an adverse reaction that may not be identified by use of an animal or computer model, the assay can provide vital information which will allow a drug company to make informed decisions earlier saving significant development costs.
Professor Dickinson said: "We've already shown this works as a way of testing new drugs for adverse immune reactions that can't be identified when tested in animal models."
Working with the National Institute of Biological Standards and Control (NIBSC) the Newcastle team have been testing monoclonal antibodies for adverse responses. Professor Dickinson added: "Our Skimune™ test would have predicted the terrible outcome at Northwick Park in 2006. Then six men taking part in a clinical trial had severe reactions to a monoclonal antibody resulting in organ failure. Previous laboratory and animal research gave no indication that this was likely to occur.
"Our test would have picked up the risk because it is a skin-based model of the human immune response."
The skin assay has been developed using cells isolated from blood samples from a range of healthy volunteers. Differentiated into dendritic cells which activate the T-cells, these in turn create a cytokine storm. Useful for fighting infection, if this immune response goes unchecked it can be extremely harmful to the individual. Skimune™ provides a histology skin damage read out enabling the severity and potency of reaction to be gauged.
Professor Richard Stebbings, principle scientist at NIBSC welcomed the development adding: "This assay offers a valuable alternative to animal models, used for safety testing of biological medicines and which are often poorly predictive of human responses."
Professor Anne Dickinson has spent 20 years working to understand how we prevent the body rejecting donor tissue such as bone marrow. This technology has been developed from a skin explant model for predicting a potentially serious complication of bone marrow transplantation, 'graft versus host' disease - a common complication following the transplant.
It has been supported by the UK's innovation agency with a Technology Strategy Board grant for the development of a prototype.
As well as patent pending the Skimune™ test, the Newcastle University team have set up a company Alcyomics Limited which aims to take the technology forward to offer personalised medicine, enabling an individual to be tested for drug responses.
More information on the technology can be found on http://www.alcyomics.com.
Inflammation Triggers Unsustainable Immune Response to Chronic Viral Infection
24.10.2016 | Universität Basel
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion
Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
24.10.2016 | Earth Sciences
24.10.2016 | Life Sciences
24.10.2016 | Physics and Astronomy